



04C0 04-26-02 #4 1614

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Frank Himmelsbach et al) Docket No.: 5/1310
Serial No. : 10/023,099) Art Unit: 1614
Filed : December 17, 2001) Examiner: to be assigned
For : Quinazoline Derivatives and Pharmaceutical Compositions Containing Them

TECH CENTER 1600/2900

APR 24 2002

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

**TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,


Timothy X. Witkowski
Attorney for Applicant(s)
Reg. No. 40,232

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-4310
Docket No.: 5/1310

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on April 15, 2002

By: 
Timothy X. Witkowski
Reg. No. 40,232

TECH CENTER
APR 16 2002

APR 24 2002

RECEIVED